ClinicalTrials.gg
CompletedNCT05515796Updated Apr 1, 2026

Multi-omics Sequencing in Neoadjuvant Immunotherapy of Gastrointestinal Tumors

A Phase 2 interventional study of Terelizumab (aka Tislelizumab) and CapeOx in Immunotherapy, Gastric Cancer and Rectal Cancer, sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University. Completed at 1 site in China. Open to participants aged 19 Years and older. Per ClinicalTrials.gov, last updated 2026-04-01.

Sponsored by Daping Hospital and the Research Institute of Surgery of the Third Military Medical University · Phase 2, Interventional, and Treatment

How we know · 7 judgments

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
189
Allocation
Non-randomized
Ages
19 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 40 studies testing trastuzumab in Stomach Neoplasms — 8 open to participants now, 10 under way, none of them phase 3. Trastuzumab · Stomach Neoplasms.

Enrollment
4th of 39
189 · median 40
Started
2022
the only one that year
Phase 2
25 of 40
5 open now
Registered
31st of 40
by date
Lead sponsor
1 of 40
Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Among the 40 studies testing trastuzumab in Stomach Neoplasms, this one is the 4th largest by enrollment of the 39 interventional ones that give a count, is the only one that started in 2022, is one of 25 in phase 2, and was the 31st registered.

Stomach Neoplasms

3,407 studies on the registry are indexed under Stomach Neoplasms; 994 are open to participants now.

Browse Stomach Neoplasms studies →

Open to participants now

8 of the 40 studies testing trastuzumab in Stomach Neoplasms are open now, in 2 countries. Recruiting first, the newest first:

3 more — sign in →

By country, each count listing its studies:

All 8 open studies →

About trastuzumab

Trastuzumab: first FDA approval 1998 (HERCEPTIN), first EMA approval 2000. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 704 Stomach Neoplasms studies recruiting now, 375 (53%) set no upper age limit and 194 (28%) stop at 75 or younger; 27 take children under 18; 70 take healthy volunteers.

This study: 19 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 40 studies testing trastuzumab in Stomach Neoplasms, or all of them as a file.
02

Study summary

immunotherapy,gastric cancer,rectal cancer,biomark

Read the detailed description

To investigate the effect of Terelizumab (aka Tislelizumab) combined with XELOX in Neoadjuvant Therapy for gastrointestinal tumors.

To explore new biomarkers that can predict the efficacy of combined immunotherapy, and to establish a clinical efficacy prediction model by means of bioinformatics to prospectively judge the efficacy and guide the follow-up individualized and accurate treatment.

03

Conditions studied

  • Immunotherapy
  • Gastric Cancer
  • Rectal Cancer
  • Chemotherapy Effect
  • Radiotherapy

Keywords

  • Immunotherapy
  • Gastric Cancer
  • Rectal Cancer
  • neoadjuvant
  • Terelizumab (aka Tislelizumab)
  • radiotherapy
  • oxaliplatin
  • capecitabine
04

Who can participate

Ages eligible
19 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • The patients are able to understand and voluntarily sign the written , which must be signed prior to the implementation of the designated research procedures required by the study.
  • The age at the time of signing the informed consent form (ICF) is ≥ 18 years old, both male and female.
  • Locally advanced or gastric / gastroesophageal junction adenocarcinoma (clinical stage ≥ T2N0M0) and pMMR/MSS(tumor immunohistochemical identified pMMR or next generation sequencing identified MSS) locally advanced rectal adenocarcinoma (clinical stage T3-4N0M0 or T1-4N+M0 ) were diagnosed by comprehensive evaluation.
  • The patients are willing to provide fresh tissue for biomarker analysis, and the tissue samples provided are of sufficient quality to evaluate the status of biomarkers. If sufficient tissue is not provided, repeated sampling may be required.
  • The patient has an performance status (ECOG PS) score of 0 or 1.
  • The expected survival time was ≥ 3 months.
  • The patient has adequate organs function

    1. The patient has adequate hematologic function, as evidenced by an (ANC) ≥1.5*10\^9/L, ≥90g/L (5.58 mmol/L), and ≥100*10\^9/L.
    2. The patient has adequate renal function as defined by a serum creatinine ≤1.5 times the , or (measured via 24-hour urine collection) ≥50 mL/minute (that is, if serum creatinine is >1.5 times the ULN, a 24-hour urine collection to calculate creatinine clearance must be performed).
    3. The patient has adequate hepatic function as defined by a total ≤1.5 mg/dL (25.65 μmol/L), and (AST) and alanine transaminase (ALT) ≤ 2.5 times the upper limit of normal (ULN; or 5.0 times the ULN in the setting of liver metastases).
    4. The patient must have adequate coagulation function as defined by (INR) ≤1.5
  • Within 7 days before the first administration, women of childbearing age must confirm that the serum pregnancy test is negative and agree to use effective during the study period and within 180 days after the last administration. In this program, women of childbearing age are defined as sexually mature women:

    1. No hysterectomy or bilateral ovariectomy
    2. Natural menopause does not last for 24 months (amenorrhea after cancer treatment does not rule out fertility) (that is, menstruation occurs at any time in the previous 24 months).

For male patients whose sexual partners are women of childbearing age, they must agree to use effective contraception during the study drug use and within 180 days after the last administration.

Exclusion criteria

Exclusion Criteria:

  • Palliative local treatment was given to non-target lesions within 2 weeks before the first administration, and systemic non-specific immunomodulatory therapy (such as interleukin, interferon, thymosin, etc.) was received within 2 weeks before the first administration. Chinese herbal medicine or proprietary Chinese medicine with anti-tumor indications was received within 2 weeks before the first administration.
  • The patient has previously received (such as anti-PD-1 antibodies, anti-PD-L1 antibodies, anti-CTLA-4 antibodies, etc.), immune checkpoint agonists (such as antibodies against ICOS, 0, CD137, GITR, OX40 targets, etc.), immune cell therapy, etc. any treatment aimed at the immune mechanism of tumor.
  • There was a history of gastrointestinal perforation and gastrointestinal fistula within 6 months before the first administration. If the perforation or fistula has been removed or repaired, and the disease has been judged by the researchers to recover or remission, it may be allowed to join the group.
  • Active or previously recorded inflammatory bowel disease (such as Crohn's disease or ulcerative colitis). Unable to swallow, malabsorption syndrome, or uncontrollable nausea, vomiting, diarrhea or other gastrointestinal diseases that seriously affect drug use and absorption.
  • There were active malignant tumors in the past 3 years, except for tumors that participated in the study and local tumors that had been cured. such as skin basal cell carcinoma, skin squamous cell carcinoma, superficial bladder cancer, cervical carcinoma in situ, breast cancer in situ, localized prostate cancer and so on.
  • Active or untreated , meningeal , spinal cord compression or diseases are known.

However, the patients who met the following requirements and had outside the central nervous system were allowed to enter the group: asymptomatic after treatment, imaging was stable for at least 4 weeks before the start of treatment (such as no new or enlarged brain metastases). And systemic and anticonvulsant drugs have been stopped for at least 2 weeks.

  • There are pleural effusion with clinical symptoms, pericardial effusion or ascites requiring frequent drainage (≥ 1 / month).
  • Study active diseases that require systematic treatment within 2 years before the start of treatment, or researchers determine the existence of autoimmune diseases that may recur or plan treatment. Except for the following:

    1. Skin diseases that do not require systematic treatment (e.g. vitiligo, hair loss, psoriasis or eczema)
    2. Hypothyroidism caused by autoimmune thyroiditis requires only a stable dose of hormone replacement therapy.
    3. Type I diabetes mellitus requiring only a stable dose of insulin replacement therapy
    4. Asthma has been completely relieved in childhood and no intervention is needed in adults.
    5. The researchers determined that the disease would not recur without external triggers.
  • There are any of the following cardio-cerebrovascular diseases or cardio-cerebrovascular risk factors:

    1. Within 6 months before the first administration, there were myocardial infarction, unstable angina pectoris, cerebrovascular accident, , acute or persistent myocardial ischemia, symptomatic heart failure (according to functional grade 2 or above), symptomatic or poorly controlled arrhythmia, or any arterial thromboembolic event.
    2. There was a history of deep venous thrombosis, pulmonary embolism or other severe thromboembolism within 3 months before the first administration.
    3. There are major vascular diseases, such as aortic aneurysm, aortic dissecting aneurysm, internal carotid artery stenosis, which may be life-threatening or require surgery within 6 months.
    4. Previous history of myocarditis and cardiomyopathy.
    5. (LVEF) \< 50%.
  • Toxicity that has not been alleviated by previous antineoplastic therapy is defined as undiminished to Grade 0 or 1 of the National Cancer Institute (NCI) General terminology Standard for adverse events () (NCICTCAEv5.0), or to the level specified in the selection / exclusion criteria, with the exception of alopecia / pigmentation. The patients who develop irreversible toxicity and are not expected to increase after drug administration (such as hearing loss) may be included in the study after consultation with researchers. Long-term toxicity caused by radiotherapy may be included in the study after consultation with the researchers who are determined by the researchers to be unable to recover.
  • Grade 2 peripheral nerve disease was defined according to NCI CTCAE v5.0 standard.
  • Interstitial lung disease or non-infectious pneumonia is known to be symptomatic or requires systemic glucocorticoid treatment in the past, and researchers have determined that it may affect toxicity assessment or management associated with research treatment.
  • Active tuberculosis is known to exist. The patients suspected of having active pulmonary tuberculosis should be examined for chest X-ray, sputum and excluded by clinical symptoms and signs.
  • Received systemic anti-infective therapy (excluding antiviral therapy for or C) within 2 weeks before the first administration.
  • The history of allogeneic organ transplantation and hematopoietic stem cell transplantation are known.
  • There are clinical active hemoptysis, active diverticulitis, abdominal abscess and gastrointestinal obstruction.
  • There were significant clinical bleeding symptoms or definite bleeding tendency within 1 month before the first administration, such as gastrointestinal bleeding, hemorrhagic gastric ulcer, or vasculitis.
  • It is known that endoscopy shows signs of active bleeding.
  • There were other major operations in addition to the diagnosis of gastric cancer within 28 days before the first administration.
  • Untreated active hepatitis B patients (HBsAg positive and HBV-DNA more than 1000 copies / ml [200IU/ml] or higher than the detection lower limit), patients with hepatitis B were required to receive anti-HBV treatment during the study treatment; active patients (HCV antibody positive and HCV-RNA levels higher than the detection lower limit).
  • Those who are known to have a history of immunodeficiency or are positive.
  • Known active syphilis infection.
  • Is participating in another clinical study, unless it is a follow-up period for observational, non-interventional clinical studies or interventional studies.
  • The patients who needed systemic treatment with glucocorticoids (> 10mg/ prednisone or equivalent dose) or other drugs within 14 days before the first administration. Except for the following:

    1. If there is no active autoimmune disease, inhaled, ophthalmic or topical glucocorticoids or doses of ≤ 10mg/ prednisone or equivalent doses of other glucocorticoids are allowed.
    2. Physiological dose of systemic glucocorticoid ≤ 10mg/ prednisone or equivalent dose of other glucocorticoids.
    3. Glucocorticoids are used as pretreatment of infusion-related reactions or allergic reactions (such as medication before CT examination).
  • The was given within 30 days of the first administration, or is planned during the study period.
  • A history of severe to other monoclonal antibodies is known.
  • It is known to be unable to meet the requirements of the trial because of mental illness or substance abuse disorder.
  • The patients who are known to have a history of allergy or hypersensitivity to drugs or any of its components in the combined immunotherapy regimen.
  • The patient is pregnant or breastfeeding.
  • The researchers believe that there may be a risk of receiving the study drug treatment, or any condition that will interfere with the evaluation of the study drug or the safety of the patients or the interpretation of the research results.
Terms in these criteria, in plain language(31)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

CD4 count

The number of CD4 cells, a type of white blood cell, in a given amount of blood. It is used to follow how well the immune system is doing in HIV.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Leptomeningeal disease

Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.

Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.

Measurable disease

The amount of disease can be tracked with a defined measurement, so the study can see whether it shrinks or grows. It might be a tumor measured on a scan or, in some blood cancers such as myeloma, a marker measured in blood or urine.

The criteria or the study team say which measurement counts — having no tumor visible on a scan does not by itself rule you out.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

CTCAE grade

The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.

1
Mild.
2
Moderate.
3
Severe.
4
Life-threatening.
5
Death due to the event.

“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Allogeneic and autologous transplant

Stem cell (bone marrow) transplants. Allogeneic uses cells from a donor; autologous uses your own cells, collected earlier and given back.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Live vaccines

Vaccines made with a weakened form of the germ, such as measles–mumps–rubella (MMR), chickenpox and yellow fever. They can be risky when the immune system is weakened. Flu injections are not live; the nasal flu spray is.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
189 participants (actual)

Study arms

  • Experimental
    Gastric cancer:CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative)

    CapeOx+Terelizumab (aka Tislelizumab)(HER2 negative): Cycle 1 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy Cycle: Day 1 through Day 21

    Drug: Terelizumab (aka Tislelizumab) · Drug: CapeOx

  • Experimental
    Gastric cancer:CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive )

    CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) (HER2 positive ): Cycle 1 up to Cycle 3 CapeOx+Trastuzumab+Terelizumab (aka Tislelizumab) Cycle: Day 1 through Day 21

    Drug: Terelizumab (aka Tislelizumab) · Drug: CapeOx · Drug: Trastuzumab

  • Experimental
    Rectal cancer:Radiotherapy with CapeOx+ Terelizumab (aka Tislelizumab)

    Rectal cancer: Cycle 1:25 Gy/5 fractions (Day 1 through Day 7) Cycle 2 up to Cycle 3 CapeOX + Terelizumab (aka Tislelizumab) therapy(Day 1 through Day 21)

    Drug: Terelizumab (aka Tislelizumab) · Drug: CapeOx · Radiation: Radiotherapy

Interventions

  • DrugTerelizumab (aka Tislelizumab)

    q3w Terelizumab (aka Tislelizumab) 200mg on day 1 of each cycle

  • DrugCapeOx

    Drug page: XeloxStudies of XeloxXelox pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Oxaliplatin(130mg/m2) on day 1 of each cycle and Capecitabine:Dose of 1000mg/m2,14days

  • q3w Trastuzumab (6 mg/kg following an initial loading dose of 8 mg/kg) on day 1 of each cycle

  • RadiationRadiotherapy

    25 Gy/5 fractions

06

What researchers measure

Primary outcomes

  1. Pathological complete response

    Pathological complete response will be evaluated with American Joint Committee on Cancer (AJCC) Cancer Staging

    Time frame: 6 months

Secondary outcomes

  1. Major pathologic response (MPR)

    It is defined as residual tumors less than 10% after neoadjuvant immunotherapy and(or) chemotherapy

    Time frame: 6 months

  2. Overall survival (OS)

    Time from study entry to death from any cause.

    Time frame: 2 years

  3. Disease-free survival (DFS)

    Time from study entry to disease recurrence or patient death due to disease progression

    Time frame: 2 years

  4. R0 resection rate

    Rate of microscopically margin-negative resection

    Time frame: 6 months

Other outcomes

  1. Correlation analysis of evaluating the relationship between clinicopathological characteristics and neoadjuvant immunochemotherapy efficacy

    Correlation analysis of evaluating the relationship between clinicopathological characteristics and neoadjuvant immunochemotherapy efficacy

    Time frame: 2 years

  2. Correlation analysis of evaluating the relationship between multi-omics analysis of tumor tissue and neoadjuvant immunochemotherapy efficacy

    Correlation analysis of evaluating the relationship between multi-omics analysis of tumor tissue and neoadjuvant immunochemotherapy efficacy

    Time frame: 2 years

  3. EORTC QLQ-C30(V3)

    Gastric cancer and rectal cancer:The EORTC Core Quality of Life questionnaire (EORTC QLQ-C30) is designed to measure cancer patients' physical, psychological and social functions.

    Time frame: 2 years

  4. EORTC QLQ-STO22

    EORTC Quality of Life Questionnaire - Gastric Cancer Module:to be used in conjunction with the EORTC QLQ-C30 to assess health-related quality of life in gastric cancer.

    Time frame: 2 years

  5. EORTC QLQ-CR29

    EORTC Quality of Life Questionnaire - Colorectal Cancer Module:to be used in conjunction with the EORTC QLQ-C30 to assess quality of life in patients with colorectal cancer

    Time frame: 2 years

07

Study locations

1 site
  • Army Medical Center
    Chongqing, Other (Non U.s.) 400000, China
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Sep 2022 to primary completion in Mar 2026, 42 months.

Of 296 non-industry phase 2 interventional studies under Stomach Neoplasms, half reached primary completion within 57 months of starting (the median), counting those still running; a quarter within 33 and three quarters within 76. This study's 42 months is below that.

Counting every sponsor, half of 361 studies reached it within 50 months; a quarter within 31 and three quarters within 75.

How these figures are worked out, and which studies are left out of them.

Registered
Aug 20, 2022
First posted
Aug 25, 2022
StartActual
Sep 1, 2022
Primary completionActual
Mar 25, 2026
CompletionActual
Mar 25, 2026
Last update
Apr 1, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 1, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05515796
Responsible party
wang bin (Director of Gastroenterology, Daping Hospital and the Research Institute of Surgery of the Third Military Medical University) — Principal investigator
First posted
Aug 25, 2022
Start date
Sep 1, 2022
Primary completion
Mar 25, 2026
Completion
Mar 25, 2026
Last update
Apr 1, 2026

Study contacts

wang bin
principal investigator · Daping Hospital and the Research Institute of Surgery of the Third Military Medical University

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Trastuzumab

Start the discussion